Clinical Trial Update: Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating whether maternal tenofovir disoproxil fumarate and emtricitabine reduce NNRTI resistance mutations after intrapartum ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtriva (emtricitabine)
• Viramune (Nevirapine)
• Viread (tenofovir disoproxil fumarate)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: HIV, Pregnancy | Phase 2 | Status: COMPLETED